These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10563382)

  • 1. [The use of oxidant-antioxidant system indices in forming groups at high genetic risk].
    Arbuzova SB; Fedotova OO; Malova SA; Krasnov AV
    Tsitol Genet; 1999; 33(4):77-80. PubMed ID: 10563382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low MSAFP and new biochemical markers for Down syndrome: implications for genetic counselors.
    Kloza EM
    Birth Defects Orig Artic Ser; 1990; 26(3):31-43. PubMed ID: 1709365
    [No Abstract]   [Full Text] [Related]  

  • 3. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A parent's guide to the genetics of Down syndrome.
    Hartway S
    Adv Neonatal Care; 2009 Feb; 9(1):27-30. PubMed ID: 19212162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current methods of prenatal screening for Down syndrome and other fetal abnormalities.
    Saller DN; Canick JA
    Clin Obstet Gynecol; 2008 Mar; 51(1):24-36. PubMed ID: 18303497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome screening: imagining the screening test of the future.
    Koster MP; Heetkamp KM; Pennings JL; de Vries A; Visser GH; Schielen PC
    Expert Rev Mol Diagn; 2010 May; 10(4):445-57. PubMed ID: 20465499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anomalous marker patterns in Down syndrome screening.
    Wald NJ; Bestwick JP; Barnes IM; Kellner LH
    Prenat Diagn; 2007 Feb; 27(2):185-6. PubMed ID: 17266168
    [No Abstract]   [Full Text] [Related]  

  • 8. Maternal serum triple analyte screening in pregnancy.
    Cate S
    Am Fam Physician; 2000 Aug; 62(4):738, 740. PubMed ID: 10969855
    [No Abstract]   [Full Text] [Related]  

  • 9. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester combined screening for Down syndrome and other fetal anomalies.
    O'Leary P; Breheny N; Dickinson JE; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Obstet Gynecol; 2006 Apr; 107(4):869-76. PubMed ID: 16582125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status.
    Selek S; Herken H; Bulut M; Ceylan MF; Celik H; Savas HA; Erel O
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):487-91. PubMed ID: 18006203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
    Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
    Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in maternal serum screening for Down syndrome.
    Messerlian GM; Canick JA
    Med Health R I; 2002 Dec; 85(12):362-5. PubMed ID: 12593353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005.
    Muller PR; Cocciolone R; Haan EA; Wilkinson C; Scott H; Sage L; Bird R; Hutchinson R; Chan A
    Am J Obstet Gynecol; 2007 Apr; 196(4):315.e1-7; discussion 285-6. PubMed ID: 17403402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Free radicals in the origin and clinical manifestation of Down's syndrome].
    Arbuzova SB
    Tsitol Genet; 1996; 30(2):25-34. PubMed ID: 9281201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human chromosome 21-specific DNA markers are useful in prenatal detection of Down syndrome.
    Liou JD; Chu DC; Cheng PJ; Chang SD; Sun CF; Wu YC; Liou WY; Chiu DT
    Ann Clin Lab Sci; 2004; 34(3):319-23. PubMed ID: 15487707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum free beta-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
    Heinig J; Steinhard J; Schmitz R; Nofer JR; Kiesel L; Klockenbusch W
    Prenat Diagn; 2007 Sep; 27(9):814-6. PubMed ID: 17554803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].
    Senat MV; Rozenberg P; Bernard JP; Ville Y
    J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.